[go: up one dir, main page]

MA56827B2 - Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine - Google Patents

Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine

Info

Publication number
MA56827B2
MA56827B2 MA56827A MA56827A MA56827B2 MA 56827 B2 MA56827 B2 MA 56827B2 MA 56827 A MA56827 A MA 56827A MA 56827 A MA56827 A MA 56827A MA 56827 B2 MA56827 B2 MA 56827B2
Authority
MA
Morocco
Prior art keywords
lurbinectedin
methods
small cell
relates
cell lung
Prior art date
Application number
MA56827A
Other languages
English (en)
Other versions
MA56827A1 (fr
Inventor
Pilar Calvo
Carmen Kahatt
José María Fernandez
Maria Tobio
Salvador Fudio
Arturo Soto
Pilar Lardelli
Cristian Fernandez
Alba Maria Del Mar Zarzuelo
Noain María De La Concepción Polanco
López Sonia Manzanaro
Honorio Velasco
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Priority claimed from PCT/EP2020/065093 external-priority patent/WO2021098992A1/fr
Publication of MA56827A1 publication Critical patent/MA56827A1/fr
Publication of MA56827B2 publication Critical patent/MA56827B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés de traitement de patients atteints de cancer du poumon à petites cellules par administration intraveineuse de quantités thérapeutiques de lurbinectédine par perfusion intraveineuse. L'invention concerne également des procédés de traitement du cancer par administration de lurbinectédine en combinaison avec d'autres médicaments anticancéreux, en particulier des inhibiteurs de la topoisomérase. L'invention concerne en outre l'administration de lurbinectédine en combinaison avec des agents antiémétique pour lutter efficacement contre les symptômes liés à la nausée et aux vomissements, des doses de lurbinectedine réduites pour obtenir une administration plus sûre et une augmentation du nombre de cycles de traitement. L'invention concerne également des formulations lyophilisées stables de lurbinectédine.
MA56827A 2019-11-21 2020-05-29 Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine MA56827B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383025 2019-11-21
PCT/EP2020/065093 WO2021098992A1 (fr) 2019-11-21 2020-05-29 Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine

Publications (2)

Publication Number Publication Date
MA56827A1 MA56827A1 (fr) 2023-01-31
MA56827B2 true MA56827B2 (fr) 2023-09-27

Family

ID=68808231

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56827A MA56827B2 (fr) 2019-11-21 2020-05-29 Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine

Country Status (4)

Country Link
US (4) US20230014782A1 (fr)
MA (1) MA56827B2 (fr)
TW (1) TW202132318A (fr)
WO (1) WO2021099635A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN202141039393A (fr) * 2021-08-31 2023-03-03
EP4433058A1 (fr) * 2021-11-15 2024-09-25 RK Pharma Inc. Procédé amélioré pour la préparation de lurbinectédine et de ses morphes
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN118388507A (zh) 2022-04-08 2024-07-26 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途
CN117263953A (zh) * 2023-09-21 2023-12-22 成都西岭源药业有限公司 一种芦比替定新晶型、其制备方法及其用途
WO2025165852A1 (fr) * 2024-01-31 2025-08-07 Navinta, Llc Formulations liquides de lurbinectédine
WO2025233522A1 (fr) 2024-05-10 2025-11-13 Pharma Mar, S.A. Procédé de synthèse d'ecteinascidine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
EP2576569B1 (fr) * 2010-05-25 2015-01-14 Pharma Mar S.A. Procédé de synthèse pour la préparation de composés ecteinascidines et intermediaires
PT2786756T (pt) * 2010-11-12 2020-05-07 Pharma Mar Sa Terapia de combinação com um inibidor de topoisomerase

Also Published As

Publication number Publication date
WO2021099635A1 (fr) 2021-05-27
MA56827A1 (fr) 2023-01-31
TW202132318A (zh) 2021-09-01
US20230014782A1 (en) 2023-01-19
US20230416276A1 (en) 2023-12-28
US20230399345A1 (en) 2023-12-14
US20230399344A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
MA56827B2 (fr) Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
SA522432668B1 (ar) طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين
JP7025416B2 (ja) 好中球減少症を低減させるための組成物および方法
EA200501203A1 (ru) Жидкие фармацевтические композиции палоносетрона
RU2015100529A (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
RU2013123646A (ru) Комбинированная композиция
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
RU2014124171A (ru) Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
ES2777250T3 (es) Método para el tratamiento del cáncer y las enfermedades concomitantes del cáncer
EA202192328A1 (ru) Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления
CN101991579A (zh) 熊果酸作为抗结肠肿瘤药物的应用
Dinota et al. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer
RU2015111907A (ru) Способ лечения хронического воспаления тканей пародонта и слизистой оболочки с элементами гиперкератоза у лиц молодого возраста
Barbieri et al. Alternativas atuais na prevenção e tratamento da xerostomia decorrente dos tratamentos antineoplásicos
US10441564B2 (en) Fructose analogs and their combinations as anti-cancer agents
CN104146999B (zh) 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用
RU2018144248A (ru) Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
RU2696287C2 (ru) Способ лечения кастрационно-устойчивого рака простаты
RU2700573C2 (ru) Способ лечения кастрационно-устойчивого рака простаты
RU2694259C2 (ru) Способ лечения кастрационно-устойчивого рака простаты
US20180125842A1 (en) Ergoloid for Cancer